Posted by Michael Wonder on 17 May 2023
Difelikefalin acetate for the treatment of patients with pruritus undergoing haemodialysis
17 May 2023 - NICE has published evidence-based recommendations on the use of difelikefalin acetate (Kapruvia) for the treatment of adults with pruritus in adults with chronic kidney disease having haemodialysis.
Difelikefalin acetate is recommended for the treatment of adults with moderate to severe pruritus with chronic kidney disease having in-centre haemodialysis. Difelikefalin acetate is only recommended if Vifor Pharma provides it according to the commercial arrangement.
